The general concept is that the interaction of PD-1 on immune cells with PD-L1 on tumor cells can lead to immune cell anergy and thus the lack of anti-tumor activity; the use of either anti-PD-1 or PD-L1 MAbs is designed to block this interaction leading to tumor cell lysis. The gene discussed is PDCD1; the disease is neoplasm.